Is Ingevity (NGVT) Undervalued Or Does Its High P/E Make It Look Expensive?
Recent price performance and what it may signal for Ingevity
Ingevity (NGVT) has seen mixed share price moves recently, with the stock down about 5% over the past month but up roughly 3% over the past 3 months and 19% over the past year.
For Ingevity, the recent 1 month share price return of about 5% down contrasts with a 15.5% share price gain year to date and an 18.9% total shareholder return over the past year, which points to momentum that has cooled slightly but remains positive overall.
Compare Ingevity's cooled momentum with other stocks that still show strong trends by scanning our hand picked 45 high quality undervalued stocks list for ideas that match your criteria.
After that mixed share price run, Ingevity now trades at about $69, while analyst and intrinsic value estimates sit meaningfully higher. Is the market being fairly cautious here, or has it pushed the stock too far below those ranges?
Most Popular Narrative: 22% Undervalued
The most followed narrative for Ingevity compares a fair value of $89 to the recent price around $69. This points to a sizeable valuation gap that analysts link to long term earnings potential.
Accelerated portfolio repositioning and the advanced stage divestiture of non core, lower margin businesses are expected to drive a step change in margin profile. This is seen as enabling greater focus and capital allocation toward higher growth, value added specialty chemicals, supporting both revenue quality and sustained EBITDA margin improvement. Structural optimization of operational footprint, resulting in lower maintenance CapEx and improved manufacturing efficiency, is freeing up cash flow while lowering cost per unit, directly enhancing free cash flow generation and improving net earnings resiliency.
Want to see what sits behind that margin reset story? The narrative leans on shifting mix, rising profitability and a future earnings multiple that is well below sector levels.
Result: Fair Value of $89 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the Ingevity narrative could be knocked off course if tariff related weakness in Advanced Polymer Technologies persists, or if portfolio sales and repositioning fail to deliver smoother earnings.
Find out about the key risks to this Ingevity narrative.
Another view of Ingevity using market multiples
The first narrative frames Ingevity as undervalued against a fair value of $89. Yet on a simple P/E basis the stock looks expensive. At about 94.7x earnings, Ingevity trades well above the US Chemicals industry at 23.7x and peers at 27.6x, and also above a fair ratio of 32.8x. That wide gap points to meaningful valuation risk if expectations reset closer to sector norms.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
If this Ingevity story feels finely balanced between optimism and caution, consider acting promptly and assessing the data for yourself. To clearly understand both perspectives, review the 4 key rewards and 3 important warning signs
Looking for more investment ideas beyond Ingevity?
If the Ingevity story has sharpened your thinking, do not stop here. Use the screeners below to spot other stocks that could deserve a closer look.
- Target stronger income potential by reviewing companies with higher yields and resilient payouts through the 12 dividend fortresses.
- Focus on financial strength by scanning the list of solid balance sheet and fundamentals (52 results) to see which stocks pair low debt with steady fundamentals.
- Get ahead of the crowd by checking the 19 high quality undiscovered gems before other investors catch on.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com